Navigation Links
Watson Confirms Exalgo™ Patent Challenge
Date:12/14/2010

MORRISTOWN, N.J., Dec. 14, 2010 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. – Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Hydromorphone Hydrochloride Extended-release Tablets, 8 mg, 12 mg, and 16 mg.  Watson's Hydromorphone Hydrochloride Extended-release Tablets are a generic version of Mallinckrodt Inc.'s Exalgo™ tablets, which are indicated for once daily administration for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

Mallinckrodt filed suit against Watson on December 10, 2010 in the United States District Court for the District of New Jersey seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent No. 5,914,131.  Mallinckrodt's lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA until April 29, 2013, or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.  

Based on available information, Watson believes it may be a "first applicant" to file an ANDA for the 8 mg, 12 mg, and 16 mg generic versions of Exalgo™ and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established an
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 30, 2015  Astellas today announced topline results ... efficacy and safety of intravenous (IV) and oral ... development for adults with candidemia and other invasive ... demonstrated that the trial did not meet its ... in isavuconazole-treated patients at the end of IV ...
(Date:7/29/2015)... 2015 Insulet Corporation (NASDAQ: PODD ), ... OmniPod ® Insulin Management System, today announced preliminary ... 2015. The Company also announced that it will postpone ... and conference call from Thursday, July 30, as originally ... Highlights: , Preliminary second quarter ...
(Date:7/29/2015)... MONICA, Calif. , July 29, 2015  UBM ... the San Diego Marriott Marquis & Marina on September ... medical device industry. A highlight of the Business Development ... Financial Backing from Different Types of Investors, featuring ... & Johnson Development Corporation; Brent Ahrens , Partner, ...
Breaking Medicine Technology:Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5Insulet Reports Preliminary Second Quarter 2015 Revenue Results 2Insulet Reports Preliminary Second Quarter 2015 Revenue Results 3Insulet Reports Preliminary Second Quarter 2015 Revenue Results 4Insulet Reports Preliminary Second Quarter 2015 Revenue Results 5MEDevice San Diego Offers Tips on Securing Financial Backing from Investors 2
... NEW YORK, Jan. 11, 2011 WebMD Health Corp. (Nasdaq: ... private placement of $400 million aggregate principal amount of 2.50% ... of notes pursuant to the exercise in full of the ... qualified institutional buyers pursuant to Rule 144A under the Securities ...
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: ... in the development, assembly, marketing and sale of medical ... that it will participate in the Arab Health Exhibition ... 2011 at the Dubai World Trade Centre in Dubai, ...
Cached Medicine Technology:WebMD Closes Offering of 2.50% Convertible Notes Due 2018 2Dehaier Medical Announces Participation in Arab Health 2011 2
(Date:7/30/2015)... ... 2015 , ... PeopleKeys, a company with over 30 years of experience in ... The webinar, the newest installment in their popular DISC for the Real World series, ... the Trainer webinar is intended for people interested in training others to use DISC ...
(Date:7/30/2015)... ... July 30, 2015 , ... Addictions Training Institute ... for people to become Certified Alcohol and Substance Abuse Counselors. , "We are thrilled ... “There is an acute shortage of Alcohol and Drug Counselors nationwide. We ...
(Date:7/29/2015)... California (PRWEB) , ... July 30, 2015 , ... Avid ... Hendrix Dorton Arena Raleigh North Carolina concert posters. The same poster art was used ... printed by Globe Poster based in Baltimore and are classic boxing style concert posters. ...
(Date:7/29/2015)... , ... July 30, 2015 , ... ... for their clients, BOC approved provider of online continuing education courses for ... offerings to their exclusive Andrews Research and Education Sports Medicine Series. , The ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to data released today by the ... is expected to remain stable at $32.50, a figure far lower than was originally ... continues to be a bright spot in American health care. By offering an abundance ...
Breaking Medicine News(10 mins):Health News:PeopleKeys to Air “Managing Stress: Train the Trainer” DISC Webinar 2Health News:Addictions Training Institute Announces New Online Certificate Program for Alcohol and Drug Counselors 2Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 2Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 3
... but often deadly disease that can strike at any time ... and in the past was referred to as a silent ... ovarian cancer that can assist in early detection. Experts at ... of preventive methods, understand the risks and recognize potential warning ...
... that the hormone estrogen may help reverse advanced pulmonary hypertension, ... million individuals in the U.S., mostly women, and can lead ... progressive increase in blood pressure in the main pulmonary artery, ... to the lungs. The rise in pressure impairs heart function ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, ... increasing rates of drug-resistant tuberculosis, health officials say the disease ... least so far. But, they add, the ease of ... one should think they,re beyond risk. "Drug-resistant TB exists ...
... The demand for transparency through publicly available healthcare data ... and clinical data for research, and for clinical trials data ... a measurable impact on research and policy making. A new ... in Electronic Health Information at the University of Ottawa and ...
... spent glued to their PlayStation 3, Xbox 360 or Nintendo ... perhaps? Improved concentration? Superior driving skills? Over the past ... action video games such as Medal of Honor or Unreal ... in a paper published this week in the journal Frontiers ...
... HealthDay Reporter , WEDNESDAY, Sept. 14 (HealthDay News) ... jumped dramatically worldwide, from about 640,000 in 1980 to more ... Over the same period, the number of cases of ... from that cancer have declined, although in 2010 it still ...
Cached Medicine News:Health News:Early detection is key in the fight against ovarian cancer 2Health News:Early detection is key in the fight against ovarian cancer 3Health News:Estrogen treatment may help reverse severe pulmonary hypertension 2Health News:Estrogen treatment may help reverse severe pulmonary hypertension 3Health News:Officials Tackle Multidrug-Resistant TB in Europe 2Health News:Officials Tackle Multidrug-Resistant TB in Europe 3Health News:New report on creating clinical public use microdata files 2Health News:Put down that Xbox remote: FSU researcher suggests video games may not boost cognition 2Health News:Put down that Xbox remote: FSU researcher suggests video games may not boost cognition 3Health News:Breast Cancer Rates Jump Worldwide, Study Finds 2Health News:Breast Cancer Rates Jump Worldwide, Study Finds 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: